{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:28:26Z","timestamp":1774466906351,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10792-020-01530-1","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T13:05:08Z","timestamp":1596027908000},"page":"3441-3451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet\u2019s disease"],"prefix":"10.1007","volume":"40","author":[{"given":"Abdullah Kursat","family":"Cingu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih Mehmet","family":"Turkcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alparslan","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Ayyildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"issue":"2","key":"1530_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0039-6257(97)00026-X","volume":"42","author":"RK George","year":"1997","unstructured":"George RK, Chan CC, Whitcup SM, Nussenblatt RB (1997) Ocular immunopathology of Behcet's disease. Surv Ophthalmol 42(2):157\u2013162","journal-title":"Surv Ophthalmol"},{"key":"1530_CR2","first-page":"1152","volume":"105","author":"H Beh\u00e7et","year":"1937","unstructured":"Beh\u00e7et H (1937) Uber rezidivierende aphthose, durch ein virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152\u20131157","journal-title":"Dermatol Wochenschr"},{"issue":"3","key":"1530_CR3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 138(3):373\u2013380","journal-title":"Am J Ophthalmol"},{"key":"1530_CR4","doi-asserted-by":"crossref","unstructured":"Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease (1990). Lancet 335 (8697):1078\u20131080","DOI":"10.1016\/0140-6736(90)92643-V"},{"issue":"3","key":"1530_CR5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT,Standardization of Uveitis Nomenclature Working G (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"1530_CR6","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-77174-3","volume-title":"Uveitis scoring system","author":"DFJ BenEzra","year":"1991","unstructured":"BenEzra DFJ, Nussenblatt RB, Tabbara K, Timonen P (1991) Uveitis scoring system. Springer, Berlin"},{"issue":"8","key":"1530_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00417-008-0823-6","volume":"246","author":"I Tugal-Tutkun","year":"2008","unstructured":"Tugal-Tutkun I, Cingu K, Kir N, Yeniad B, Urgancioglu M, Gul A (2008) Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 246(8):1169\u20131177. https:\/\/doi.org\/10.1007\/s00417-008-0823-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1530_CR8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C (2005) Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 50(4):297\u2013350","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"1530_CR9","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","volume":"91","author":"N Kitaichi","year":"2007","unstructured":"Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Behcet's disease: an international collaborative study. Br J Ophthalmol 91(12):1579\u20131582","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1530_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3109\/09273948.2012.713159","volume":"20","author":"AK Cingu","year":"2012","unstructured":"Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I (2000s) Comparison of presenting features and three-year disease course in Turkish patients with Behcet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 20(6):423\u2013428. https:\/\/doi.org\/10.3109\/09273948.2012.713159","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"1530_CR11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0161-6420(97)30249-8","volume":"104","author":"H Demiroglu","year":"1997","unstructured":"Demiroglu H, Barista I, Dundar S (1997) Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 104(4):701\u2013705","journal-title":"Ophthalmology"},{"issue":"4","key":"1530_CR12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2003.07.018","volume":"111","author":"A Yoshida","year":"2004","unstructured":"Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (1990s) Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology 111(4):810\u2013815","journal-title":"Ophthalmology"},{"key":"1530_CR13","first-page":"880","volume":"16","author":"W Chi","year":"2010","unstructured":"Chi W, Yang P, Zhu X, Wang Y, Chen L, Huang X, Liu X (2010) Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. Mol Vis 16:880\u2013886","journal-title":"Mol Vis"},{"issue":"7","key":"1530_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/IAE.0b013e31823496a3","volume":"32","author":"JH Bae","year":"2012","unstructured":"Bae JH, Lee SC (2012) Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina 32(7):1395\u20131402. https:\/\/doi.org\/10.1097\/IAE.0b013e31823496a3","journal-title":"Retina"},{"issue":"4","key":"1530_CR15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5692\/clinicalneurol.51.261","volume":"51","author":"S Kadowaki","year":"2011","unstructured":"Kadowaki S, Matsuda N, Moriya A, Ebitani M, Yoshihara A, Nakamura K, Mochizuki H, Ugawa Y (2011) Infliximab treatment trial in a patient with neuro-Behcet's disease unresponsive to other treatments. Rinsho Shinkeigaku 51(4):261\u2013266","journal-title":"Rinsho Shinkeigaku"},{"issue":"5","key":"1530_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1600-0714.2009.00774.x","volume":"38","author":"A Sun","year":"2009","unstructured":"Sun A, Wang YP, Chia JS, Liu BY, Chiang CP (2009) Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease. J Oral Pathol Med 38(5):401\u2013405","journal-title":"J Oral Pathol Med"},{"issue":"3","key":"1530_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10067-008-1070-2","volume":"28","author":"T Gono","year":"2009","unstructured":"Gono T, Murata M, Kawaguchi Y, Wakasugi D, Soejima M, Yamanaka H, Hara M (2009) Successful treatment for sympathetic storms in a patient with neuro-Behcet's disease. Clin Rheumatol 28(3):357\u2013359. https:\/\/doi.org\/10.1007\/s10067-008-1070-2","journal-title":"Clin Rheumatol"},{"issue":"438","key":"1530_CR18","first-page":"S20","volume":"23","author":"I Kotter","year":"2005","unstructured":"Kotter I, Koch S, Vonthein R, Ruckwaldt U, Amberger M, Gunaydin I, Zierhut M, Stubiger N (2005) Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 23(438):S20\u2013S26","journal-title":"Clin Exp Rheumatol"},{"issue":"5032","key":"1530_CR19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.1948049","volume":"254","author":"R Kuhn","year":"1991","unstructured":"Kuhn R, Rajewsky K, Muller W (1991) Generation and analysis of interleukin-4 deficient mice. Science 254(5032):707\u2013710","journal-title":"Science"},{"issue":"7","key":"1530_CR20","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/art.20334","volume":"50","author":"M Ben Ahmed","year":"2004","unstructured":"Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H (2004) Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum 50(7):2291\u20132295. https:\/\/doi.org\/10.1002\/art.20334","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1530_CR21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1346-8138.2003.tb00442.x","volume":"30","author":"BC Aridogan","year":"2003","unstructured":"Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S (2003) Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behcet's disease. J Dermatol 30(8):602\u2013607","journal-title":"J Dermatol"},{"issue":"6","key":"1530_CR22","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1365-3083.2011.02532.x","volume":"73","author":"HB Oral","year":"2011","unstructured":"Oral HB, Dilek K, Ozcimen AA, Taskapilioglu O, Bingol U, Sarandol A, Saricaoglu H, Yurtkuran M, Yurtkuran MA (2011) Interleukin-4 gene polymorphisms confer Behcet's disease in Turkish population. Scand J Immunol 73(6):594\u2013601. https:\/\/doi.org\/10.1111\/j.1365-3083.2011.02532.x","journal-title":"Scand J Immunol"},{"issue":"10","key":"1530_CR23","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood.V87.10.4286.bloodjournal87104286","volume":"87","author":"B Schnyder","year":"1996","unstructured":"Schnyder B, Lugli S, Feng N, Etter H, Lutz RA, Ryffel B, Sugamura K, Wunderli-Allenspach H, Moser R (1996) Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 87(10):4286\u20134295","journal-title":"Blood"},{"issue":"1","key":"1530_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cyto.2015.05.018","volume":"75","author":"RD May","year":"2015","unstructured":"May RD, Fung M (2015) Strategies targeting the IL-4\/IL-13 axes in disease. Cytokine 75(1):89\u2013116. https:\/\/doi.org\/10.1016\/j.cyto.2015.05.018","journal-title":"Cytokine"},{"issue":"5","key":"1530_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.humimm.2015.03.011","volume":"76","author":"K Hamzaoui","year":"2015","unstructured":"Hamzaoui K, Bouali E, Hamzaoui A (2015) Interleukin-33 and Behcet disease: another cytokine among others. Hum Immunol 76(5):301\u2013306. https:\/\/doi.org\/10.1016\/j.humimm.2015.03.011","journal-title":"Hum Immunol"},{"issue":"3 Suppl 77","key":"1530_CR26","first-page":"6","volume":"31","author":"K Hamzaoui","year":"2013","unstructured":"Hamzaoui K, Kaabachi W, Fazaa B, Zakraoui L, Mili-Boussen I, Haj-Sassi F (2013) Serum IL-33 levels and skin mRNA expression in Behcet's disease. Clin Exp Rheumatol 31(3 Suppl 77):6\u201314","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"1530_CR27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3346\/jkms.2013.28.8.1145","volume":"28","author":"DJ Kim","year":"2013","unstructured":"Kim DJ, Baek SY, Park MK, Park KS, Lee JH, Park SH, Kim HY, Kwok SK (2013) Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease. J Korean Med Sci 28(8):1145\u20131153. https:\/\/doi.org\/10.3346\/jkms.2013.28.8.1145","journal-title":"J Korean Med Sci"},{"issue":"6","key":"1530_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/cmi.2014.31","volume":"11","author":"K Hamzaoui","year":"2014","unstructured":"Hamzaoui K, Borhani-Haghighi A, Kaabachi W, Hamzaoui A (2014) Increased interleukin 33 in patients with neuro-Behcet's disease: correlation with MCP-1 and IP-10 chemokines. Cell Mol Immunol 11(6):613\u2013616. https:\/\/doi.org\/10.1038\/cmi.2014.31","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"1530_CR29","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.1944","volume":"11","author":"MF Nold","year":"2010","unstructured":"Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11(11):1014\u20131022. https:\/\/doi.org\/10.1038\/ni.1944","journal-title":"Nat Immunol"},{"issue":"4","key":"1530_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.22034\/IJI.2019.80281","volume":"16","author":"I Ben Dhifallah","year":"2019","unstructured":"Ben Dhifallah I, Borhani-Haghighi A, Hamzaoui A, Hamzaoui K (2019) Decreased Level of IL-37 correlates negatively with inflammatory cytokines in cerebrospinal fluid of patients with neuro-Behcet's disease. Iran J Immunol 16(4):299\u2013310. https:\/\/doi.org\/10.22034\/IJI.2019.80281","journal-title":"Iran J Immunol"},{"key":"1530_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clim.2018.03.016","volume":"192","author":"O Kacem","year":"2018","unstructured":"Kacem O, Kaabachi W, Dhifallah IB, Hamzaoui A, Hamzaoui K (2018) Elevated expression of TSLP and IL-33 in Behcet's disease skin lesions: IL-37 alleviate inflammatory effect of TSLP. Clin Immunol 192:14\u201319. https:\/\/doi.org\/10.1016\/j.clim.2018.03.016","journal-title":"Clin Immunol"},{"issue":"6","key":"1530_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/ni.2617","volume":"14","author":"P Licona-Limon","year":"2013","unstructured":"Licona-Limon P, Kim LK, Palm NW, Flavell RA (2013) TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 14(6):536\u2013542. https:\/\/doi.org\/10.1038\/ni.2617","journal-title":"Nat Immunol"},{"issue":"2","key":"1530_CR33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0181-5512(06)73762-7","volume":"29","author":"H Guenane","year":"2006","unstructured":"Guenane H, Hartani D, Chachoua L, Lahlou-Boukoffa OS, Mazari F, Touil-Boukoffa C (2006) Production of Th1\/Th2 cytokines and nitric oxide in Behcet's uveitis and idiopathic uveitis. J Fr Ophtalmol 29(2):146\u2013152","journal-title":"J Fr Ophtalmol"},{"issue":"4","key":"1530_CR34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0181-5512(08)71433-5","volume":"31","author":"H Belguendouz","year":"2008","unstructured":"Belguendouz H, Messaoudene D, Hartani D, Chachoua L, Ahmedi ML, Lahmar-Belguendouz K, Lahlou-Boukoffa O, Touil-Boukoffa C (2008) Effect of corticotherapy on interleukin-8 and -12 and nitric oxide production during Behcet and idiopathic uveitis. J Fr Ophtalmol 31(4):387\u2013395","journal-title":"J Fr Ophtalmol"},{"issue":"10","key":"1530_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","volume":"11","author":"ZY Zhou","year":"2012","unstructured":"Zhou ZY, Chen SL, Shen N, Lu Y (2012) Cytokines and Behcet's disease. Autoimmun Rev 11(10):699\u2013704. https:\/\/doi.org\/10.1016\/j.autrev.2011.12.005","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1530_CR36","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/sj.jid.5700281","volume":"126","author":"CC Zouboulis","year":"2006","unstructured":"Zouboulis CC (2006) HLA-independent antibacterial host response toward Th1 immunity mediated by IL-12: a new concept for the pathogenesis of adamantiades-Behcet's disease. J Invest Dermatol 126(7):1444\u20131447. https:\/\/doi.org\/10.1038\/sj.jid.5700281","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1530_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdermsci.2003.12.004","volume":"34","author":"H Yanagihori","year":"2004","unstructured":"Yanagihori H, Tojo M, Inoue T, Nakamura K, Kaneko F, Nishida T, Mizuki N (2004) Lack of association of interleukin-12 p40 gene (IL12B) polymorphism with Behcet's disease in the Japanese population. J Dermatol Sci 34(2):112\u2013114. https:\/\/doi.org\/10.1016\/j.jdermsci.2003.12.004","journal-title":"J Dermatol Sci"},{"issue":"6","key":"1530_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nm1585","volume":"13","author":"A Amadi-Obi","year":"2007","unstructured":"Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1. Nat Med 13(6):711\u2013718. https:\/\/doi.org\/10.1038\/nm1585","journal-title":"Nat Med"},{"issue":"9","key":"1530_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ni1375","volume":"7","author":"M Batten","year":"2006","unstructured":"Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N (2006) Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7(9):929\u2013936. https:\/\/doi.org\/10.1038\/ni1375","journal-title":"Nat Immunol"},{"issue":"2","key":"1530_CR40","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4049\/jimmunol.182.2.1041","volume":"182","author":"N Ouaked","year":"2009","unstructured":"Ouaked N, Mantel PY, Bassin C, Burgler S, Siegmund K, Akdis CA, Schmidt-Weber CB (2009) Regulation of the foxp3 gene by the Th1 cytokines: the role of IL-27-induced STAT1. J Immunol 182(2):1041\u20131049","journal-title":"J Immunol"},{"issue":"8","key":"1530_CR41","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1167\/iovs.12-9863","volume":"53","author":"C Wang","year":"2012","unstructured":"Wang C, Tian Y, Lei B, Xiao X, Ye Z, Li F, Kijlstra A, Yang P (2012) Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease. Investig Ophthalmol Vis Sci 53(8):4668\u20134675. https:\/\/doi.org\/10.1167\/iovs.12-9863","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"1530_CR42","doi-asserted-by":"publisher","first-page":"e1001395","DOI":"10.1371\/journal.pbio.1001395","volume":"10","author":"M Corvaisier","year":"2012","unstructured":"Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, Garo E, Hoppe E, Barre B, Audran M, Bouvard B, Saint-Andre JP, Jeannin P (2012) IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol 10(9):e1001395. https:\/\/doi.org\/10.1371\/journal.pbio.1001395","journal-title":"PLoS Biol"},{"issue":"6","key":"1530_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00005-015-0362-x","volume":"63","author":"T Yamagata","year":"2015","unstructured":"Yamagata T, Skepner J, Yang J (2015) Targeting Th17 effector cytokines for the treatment of autoimmune diseases. Arch Immunol Ther Exp (Warsz) 63(6):405\u2013414. https:\/\/doi.org\/10.1007\/s00005-015-0362-x","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"1530_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.imlet.2017.08.008","volume":"190","author":"W Kaabachi","year":"2017","unstructured":"Kaabachi W, Bouali E, Berraies A, Dhifallh IB, Hamdi B, Hamzaoui K, Hamzaoui A (2017) Interleukin-26 is overexpressed in Behcet's disease and enhances Th17 related -cytokines. Immunol Lett 190:177\u2013184. https:\/\/doi.org\/10.1016\/j.imlet.2017.08.008","journal-title":"Immunol Lett"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-020-01530-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T23:08:16Z","timestamp":1627513696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-020-01530-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01530-1","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"1 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of \u0131nterest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}